All In Biotech

Drug Trial Radar · NCT00051012

Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients

A Multicenter Open-Label Study to Evaluate the Safety and Efficacy of DAB389IL-2 in Cutaneous T-Cell Lymphoma (CTCL) Patients Following Protocol 93-04-10, Protocol 93-04-11, or Protocol 92-04-01 or Who Meet the Requirements for Protocol 93-04-11 Except Have Biopsy-Documented CTCL That Does Not Express CD25

Last checked: Nov 20, 2026Latest source record: Mar 5, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

86

Actual

Start

Sep 1995

Primary completion

Oct 2006

Study completion Dec 2006

Sponsor

Lead sponsor
Eisai Inc.Eisai
Sponsor type
Industry
First posted
Jan 3, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide an opportunity for patients who exhibit progressive disease while receiving placebo on the companion 93-04-11 study to receive ONTAK. It is also designed to determine the effectiveness of ONTAK in Cutaneous T-cell Lymphoma (CTCL) patients whose tumors do not express CD25.

Conditions

  • Lymphoma, T-Cell, Cutaneous
  • Mycosis Fungoides
  • Sezary Syndrome

Interventions

  • ONTAKDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Rate of Response (ORR), defined as CR + CCR + PR

Locations

34 sites in 9 countries. Site status is shown where the registry gives one.

  • University of Texas, M.D. Anderson Cancer Center

    Houston, Texas

  • Level 4 Department of Haematology Royal North Shore Hospital

    Saint Leonard's, New South Wales, Australia

  • Westmead Hospital, Department of Haematology

    Westmead, New South Wales, Australia

  • Mater Misericordiae Adult Hospital

    South Brisbane, Queensland, Australia

  • Oncology Haematology Radiation Oncology Unit, Princess Alexandra Hospital

    Woolloongabba, Queensland, Australia

  • Peter MacCallum Cancer Institute

    Melbourne, Victoria, Australia

  • LKH Universitatsklinikum Graz

    Graz, Austria

  • Allgemeines Krankenhaus der Stadt Wien

    Vienna, Austria

  • Cross Cancer Centre

    Edmonton, Alberta, Canada

  • Hamilton Regional Cancer Center

    Hamilton, Ontario, Canada

  • Jewish General Hospital

    Montreal, Quebec, Canada

  • Universitatsklinikum Charite

    Berlin, Germany

  • University of Erlangen

    Erlangen, Germany

  • Universitatsklinikum Essen

    Essen, Germany

  • J.W. Goethe University Frankfurt

    Frankfurt, Germany

  • Universitatskrankenhaus Eppendorf

    Hamburg, Germany

  • Universitatsklinikum Mannheim

    Mannheim, Germany

  • Universitatsklinikum Munster

    Münster, Germany

  • Medical Academy in Gdansk, Dept. of Hematology

    Gdansk, Poland

  • Regional Oncological Center, Dept. of Chemotherapy

    Lodz, Poland

  • Klinika Hematoonkologii Akademii Medycznej w Lublinie

    Lublin, Poland

  • Oddzial Chorob Wewnetrznych i Hematologii

    Poznan, Poland

  • The Medical University of Warsaw, Central Clinical Hospital

    Warsaw, Poland

  • Centrum Onkologii-Instytut im. Marii Sklodoskiej-Curie

    Warsaw, Poland

  • Blokhin Russian Cancer Research Center, RAMS

    Moscow, Russia

  • Burdenko Main Military Clinical Hospital

    Moscow, Russia

  • Central Research Institute of Skin and Venereal Diseases

    Moscow, Russia

  • Haematology Research Center RAMS

    Moscow, Russia

  • St. Petersburg Pavlov State Medical University

    Saint Petersburg, Russia

  • Samara Regional Clinical Hospital

    Samara, Russia

  • Universitatsspital Zurich Dermatologische Klinik

    Zurich, Switzerland

  • St. John's Institute of Dermatology

    London, United Kingdom

  • City Hospital

    Nottingham, United Kingdom

  • Southampton General Hospital

    Southampton, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.